JARI Pharmaceutical Co, Ltd.’s antineoplastic API Pemetrexed Disodium was approved by the National Medical Products Administration

- Nov 13, 2020-

On October 20, 2020, the antineoplastic API "Pemetrexed Disodium" independently developed by JARI Pharmaceutical was successfully approved by NMPA! This is another JARI’s approved product after the approval of API "Bicalutamide" in 2020.

 

The successful approval of API Pemetrexed Disodium this time fully demonstrates the advanced level and ability of JARI Pharmaceutical in the R&D and production of APIs, and will Lay a solid foundation for undertaking more MAH (Marketing Authorization Holder) projects in the future. Also it further enhances the competitiveness of JARI Pharmaceutical in the API market.